MIPI Calculator
Mantle Cell Lymphoma International Prognostic Index for risk assessment
Calculate MIPI Score
Patient's age at diagnosis
Fully active, no restrictions
Lactic acid dehydrogenase level
Laboratory's upper normal limit (typically 160 U/L)
Normal range: 4.3-10.8 ×1000/µL
Ki-67 is used to calculate MIPI-b (biologic MIPI) for more accurate prognosis
MIPI Results
Formula used: MIPI = 0.03535 × age + [1.367 × log₁₀(LDH/ULN) + 0.9393 × log₁₀(WBC)]
Medical Disclaimer: This calculator is for educational purposes only and provides statistical estimates based on historical data. Individual outcomes may vary significantly. Always consult with an oncologist for proper diagnosis and treatment planning.
Risk Group Classifications
Example Case
Patient Steven (65 years old)
Age: 65 years
ECOG: 1 (symptoms present, can do light work)
LDH: 2500 U/L
ULN LDH: 160 U/L
WBC: 20 ×1000/µL
Calculation Result
MIPI = 0.03535 × 65 + 0.6978 + [1.367 × log₁₀(2500/160) + 0.9393 × log₁₀(20)]
MIPI = 7.97
Risk Group: High Risk
Median Survival: 29 months
ECOG Performance Status
Fully active, no restrictions
Restricted in strenuous activity, ambulatory and able to light work
Ambulatory >50% of waking hours, unable to work, can care for self
Limited self-care, confined to bed/chair >50% of waking hours
Completely disabled, confined to bed/chair, cannot care for self
Normal Laboratory Values
LDH (Lactic Acid Dehydrogenase)
Normal: 140-280 U/L
Common ULN: 160 U/L
White Blood Cells (WBC)
Normal: 4.3-10.8 ×1000/µL
Ki-67 Proliferation Index
Low: <30%
High: ≥30%
Treatment Considerations
Low risk: Standard immunochemotherapy may be sufficient
Intermediate risk: Consider intensified treatment approaches
High risk: Aggressive treatment and targeted therapies indicated
Consider clinical trials for novel treatments
Understanding MIPI and Mantle Cell Lymphoma
What is MIPI?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a validated scoring system used to assess prognosis and guide treatment decisions in patients with mantle cell lymphoma (MCL). It was developed based on analysis of 455 patients with advanced-stage MCL.
Clinical Applications
- •Risk stratification at diagnosis
- •Treatment planning and intensity selection
- •Patient counseling and prognosis discussion
- •Clinical trial stratification
MIPI Components
MIPI = 0.03535 × age + ECOG component + LDH component + WBC component
Where ECOG component = 0.6978 if ECOG > 1, otherwise 0
- Age: Patient age at diagnosis (continuous variable)
- ECOG PS: Performance status (0-4 scale)
- LDH: Serum lactate dehydrogenase level
- WBC: White blood cell count
- Ki-67: Optional proliferation marker for MIPI-b
About Mantle Cell Lymphoma
Mantle cell lymphoma is a rare and aggressive B-cell non-Hodgkin lymphoma that typically affects older adults. It accounts for approximately 6% of all non-Hodgkin lymphomas and is characterized by the translocation t(11;14) involving the cyclin D1 gene.
- Median age: 65-70 years
- Male predominance: 3-4:1 ratio
- Common sites: Lymph nodes, spleen, GI tract
- Prognosis: Variable, improved with modern therapies
MIPI vs MIPI-b
MIPI-b (biologic MIPI) incorporates the Ki-67 proliferation index in addition to the four standard MIPI variables, providing enhanced prognostic accuracy.
- MIPI: Age, ECOG, LDH, WBC
- MIPI-b: MIPI + Ki-67 proliferation index
- Ki-67 <30%: Lower proliferation, better prognosis
- Ki-67 ≥30%: Higher proliferation, worse prognosis
Important Limitations
- • MIPI was developed in the era of conventional chemotherapy; modern targeted therapies may improve outcomes
- • Individual patient outcomes may vary significantly from population-based estimates
- • MIPI does not incorporate molecular markers beyond Ki-67
- • Should be used in conjunction with other clinical factors and judgment